Brief: Egetis Therapeutics 9M Adjusted EPS SEK -0.8
08/11/2024 06:00
Nov 08 (Reuters) - Egetis Therapeutics 9M net income SEK -233.1 million. * 9M revenue SEK 35.3 million
Recent news on Egetis Therapeutics AB (publ)
See all newsBrief: Egetis Announces Grant Of Patent For MCT8 Deficiency Composition In U.S.
Swedisg drugmaker Egetis's Q1 revenue rises 9% on Emcitate sales in Europe
Brief: Egetis Therapeutics Q1 Loss SEK 94.5 Mln
Brief: Egetis Plans Directed Share Issue Raising SEK 350 Million
Brief: Egetis Therapeutics Appoints Tiago Nunes As CMO Effective May 1